The European Medicines Agency (EMA) has recently published Version 1 of the EU IDMP Implementation Guide, which aims to inform stakeholders about the specification, data elements, and associated business rules to help prepare for the implementation of ISO IDMP standards.

We’ve written quite a few times about the new ISO IDMP standards that are set to be released soon. These standards will change how life science organizations manage drug information and safety throughout the EU.

The European Medicines Agency (EMA) has recently published Version 1 of the EU IDMP Implementation Guide, which aims to inform stakeholders about the specification, data elements, and associated business rules to help prepare for the implementation of ISO IDMP standards. It reflects current understanding based on ongoing discussions at the SPOR (ISO IDMP) Task Force.

The guide focuses on the processes for agnostics and does not contain information on the process for submission, exchange, or validation of medicinal product information. EU IG v2 will contain the operating model for PMS.

While the rules, data, and specifications are expected to be stable, they are still officially a version 1.0 release and may be subject to some modifications over the coming months, as all parts of the documentation are subject to development and testing (e.g., Medical Devices, Reference Strengths).

The key for the first version is to promote awareness and transparency of the work of the SPOR Task Force. You can read the full guide here, but here are a few things you can learn:

  • The scope, legal basis, and implementation of ISO IDMP.
  • Guidance on which data fields and business rules must be submitted.
  • Technical specifications on structure and format, including a description of principles, security, resources, calls, and endpoints for the API.
  • Guidance on migration between xEVMPD and PMS, including backward compatibility rules.

EMA is currently developing version two ('EU IG v2'), which will provide more information, including the basis for medicinal product data exchange in the EU. Version two is expected to cover maintenance, data quality assurance, data access and export rules, and some examples that companies can use for understanding the process.

EXTEDOpulse solutions are the perfect answer to constantly changing regulations and submission formats.

whiteWaveTop

Latest Blog Posts

500

Singapore's Transition to eCTD

500

Bertelsmann Investments Announces Another Major Investment in the Growing Pharma Tech Market

500

Interview: Meet EXTEDO’s Regulatory Intelligence (RI) Module!

500

Optimizing Life Sciences: EXTEDOpulse powered by CARA Unleashes the Power of Master Data Management in Regulatory Information Management (RIM)